David P. Meeker
CIK: 0001385155
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (22 total)
- Sep 14, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.8K shares at avg. $104.55$190K - Sep 14, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct8.7K shares at avg. $103.43$900K - Sep 14, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct2.3K shares at avg. $105.19$242K - Sep 14, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct50K shares at avg. $6.05$303K - Sep 14, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct6.4K shares at avg. $101.75$655K - Sep 14, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct30.7K shares at avg. $102.35$3.1M - Jun 17, 2026KARD
Kardigan, Inc.
Award(A)Direct20.7K shares- - Jun 3, 2026TRVI
Trevi Therapeutics, Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
35K shares- - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Options (Right to Buy)
107.9K shares- - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
71.9K shares- - Feb 1, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct68.7K shares- - Feb 1, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Tax Payment(F)Direct31.5K shares at avg. $108.99$3.4M - Jun 11, 2025TRVI
Trevi Therapeutics, Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
45K shares- - Jun 3, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct43.6K shares at avg. $4.59$200K - Jun 3, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct274 shares at avg. $65.60$18K - Jun 3, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct43.3K shares at avg. $65.04$2.8M - Feb 19, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct9.9K shares at avg. $57.22$566K - Feb 16, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct21.3K shares- - Feb 14, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
133.4K shares- - Feb 14, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Options (Right to Buy)
200K shares- - Feb 4, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct4.3K shares at avg. $59.43$254K - Feb 1, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct14.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,817 | $104.55 | $189,965 | Direct |
| Sep 14, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 8,698 | $103.43 | $899,634 | Direct |
| Sep 14, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 2,300 | $105.19 | $241,937 | Direct |
| Sep 14, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 50,000 | $6.05 | $302,500 | Direct |
| Sep 14, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 6,439 | $101.75 | $655,145 | Direct |
| Sep 14, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 30,746 | $102.35 | $3,146,761 | Direct |
| Jun 17, 2026 |  KARD Kardigan, Inc. | Award(A) | 20,706 | - | $0 | Direct |
| Jun 3, 2026 |  TRVI Trevi Therapeutics, Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 35,000 | - | - | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Options (Right to Buy) | 107,850 | - | - | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 71,900 | - | - | Direct |
| Feb 1, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 68,713 | - | $0 | Direct |
| Feb 1, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Tax Payment(F) | 31,522 | $108.99 | $3,435,583 | Direct |
| Jun 11, 2025 | TRVI Trevi Therapeutics, Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 45,000 | - | - | Direct |
| Jun 3, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 43,620 | $4.59 | $200,216 | Direct |
| Jun 3, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 274 | $65.60 | $17,975 | Direct |
| Jun 3, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 43,346 | $65.04 | $2,819,358 | Direct |
| Feb 19, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 9,896 | $57.22 | $566,249 | Direct |
| Feb 16, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 21,250 | - | - | Direct |
| Feb 14, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 133,350 | - | - | Direct |
| Feb 14, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Options (Right to Buy) | 200,000 | - | - | Direct |
| Feb 4, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 4,278 | $59.43 | $254,242 | Direct |
| Feb 1, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 14,125 | - | - | Direct |
1-22 of 22 transactions
About Meeker David P
Meeker David P (SEC CIK 0001385155) files insider reports with the SEC as President and CEO of RHYTHM PHARMACEUTICALS, INC. (RYTM), Director of Kardigan, Inc. (KARD) and Director of Trevi Therapeutics, Inc. (TRVI). Signal8 also holds filings tied to 1 other company.
Signal8 holds 11 ownership filings by Meeker David P (2 Form 3, 9 Form 4), filed between Feb 4, 2025 and Sep 14, 2026. Those filings report 22 transactions, from Feb 1, 2025 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Meeker David P's filings is in BOSTON, MA.
Recent filings by Meeker David P
- Sep 14, 2026: Open-market sales of RYTM shares (3 lines, Form 4, code S).
- Sep 14, 2026: Option exercise of RYTM shares (Form 4, code M).
- Sep 14, 2026: Open-market sales of RYTM shares (2 lines, Form 4, code S).
- Jun 17, 2026: Grant or award of KARD shares (Form 4, code A).
- Jun 3, 2026: Grant or award of TRVI derivative securities (Form 4, code A).
Other insiders filing for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Smith Hunter C, Chief Financial Officer
- Joshi Manher, Chief Medical Officer
- Shulman Joseph, Chief Technical Officer
- Garfield Alastair, Chief Scientific Officer
- Lee Jennifer Kayden, EVP, Head of North America
- Mazabraud Yann, EVP, Head of International